肠促胰岛素可预测EDEN试验中肠内营养策略的应答
该研究为EDEN试验的二次分析,旨在探讨肠促胰岛素是否可预测急性呼吸窘迫综合征(ARDS)患者对肠内营养策略的异质性治疗效应。研究纳入889例患者,结果显示葡萄糖依赖性促胰岛素多肽(GIP)可预测异质性治疗效应(校正交互作用P=0.01),最高GIP三分位患者接受滋养性喂养的死亡率低于全量喂养(14.1% vs 27.2%)。GLP-1、ARDS亚表型及基线死亡风险未预测异质性治疗效应。
要点
- GIP可预测ARDS患者对滋养性与全量肠内营养的异质性治疗效应。
- 最高GIP三分位患者中,滋养性喂养死亡率低于全量喂养(14.1% vs 27.2%)。
- GLP-1、ARDS亚表型及基线死亡风险未预测异质性治疗效应。
核心结论
- 在EDEN试验中,GIP是唯一可预测肠内营养策略异质性治疗效应的肠促胰岛素,可能作为指导ARDS患者肠内营养水平的生物标志物,但需进一步验证。
研究设计与样本
- EDEN试验的二次分析,纳入889例ARDS患者,随机分为滋养性喂养组(452例)和全量肠内营养组(437例)。
主要发现
- GIP预测异质性治疗效应(校正交互作用P=0.01),最高GIP三分位患者接受滋养性喂养的死亡率低于全量喂养(14.1% vs 27.2%),其他三分位死亡率相似。
- GLP-1、ARDS亚表型及基线死亡风险未预测异质性治疗效应。
关键数值与推荐
- 主要结局为60天死亡率,交互作用分析校正了人口学特征、疾病严重程度、糖尿病及循环白细胞介素-6。
- GIP预测异质性治疗效应的校正交互作用P值为0.01。
临床怎么用
- GIP可能作为生物标志物指导ARDS患者肠内营养水平的选择,但需进一步研究验证后方可用于临床决策。
局限性
- 本研究为二次分析,结论需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: The Early versus Delayed Enteral Nutrition (EDEN) trial found no significant difference in mortality between trophic and full enteral nutrition strategies in acute respiratory distress syndrome (ARDS) patients. Heterogeneity of treatment effect (HTE) has been identified in prior ARDS trials. We previously identified intestine-derived incretin hormones (glucose-dependent insulinotropic peptide [GIP] and glucagon-like peptide [GLP]-1 as potential predictive biomarkers in the response to nutrition. OBJECTIVES: To investigate incretins as biomarkers predictive of HTE in EDEN. METHODS: GIP, GLP-1, and host immune response biomarkers were measured from pre-intervention EDEN plasma samples. We investigated HTE with 60-day mortality as a primary outcome by testing interaction of treatment with circulating incretin levels in analyses adjusted for demographics, severity of illness, diabetes mellitus, and circulating interleukin-6, and assessed mortality by treatment arm across incretin tertiles. We additionally tested for HTE by de novo ARDS subphenotypes and by risk of mortality. MEASUREMENTS & MAIN RESULTS: 889 participants were included (452 randomized to trophic and 437 to full enteral nutrition). GIP predicted HTE to enteral nutrition strategies (adjusted interaction p-value 0.01) with lower mortality from trophic feeds (14.1% vs 27.2% in full) in patients in the highest GIP tertile but similar mortality in other tertiles. GLP-1, ARDS subphenotypes, and baseline risk of mortality did not predict HTE. CONCLUSIONS: GIP was unique among incretins in predicting HTE to enteral nutrition strategies in EDEN. Further studies are needed to validate our findings as GIP might serve as a biomarker to guide level of enteral nutrition for ARDS patients.
引用
- Hansell CE, Aneis HA, Yang Z, et al. Incretins Predict Response to Enteral Nutrition Strategies in the EDEN Trial: A Secondary Analysis. Am J Respir Crit Care Med. 2026. PMID: 42439515. doi:10.1093/ajrccm/aamag366
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。